Australia
Registrational Phase III AMPLIFY trial: Target number of participants achieved
SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III A...
2026-03-10 21:02
6470
Faybl launches in US, offering RIAs chance to shape the future of AI-powered advice
* Faybl delivers proven efficiency gains of up to 70 percent in support of US advice industry that is struggling for capacity * Faybl has grown Australian user base by 50 percent; already testing V2 in home market * Anthony Lipp announced as new Adviser * Faybl's leadership team will be at...
2026-03-10 20:00
4372
Westpac to change the format of its long-term USD funding
SYDNEY, March 5, 2026 /PRNewswire/ -- Westpac Banking Corporation ("Westpac") today announced its intention to voluntarily deregister from the United States Securities and Exchange Commission (the "SEC") by filing a Form 15F with the SEC as early asMay 2026. Upon filing the Form 15F, Westpac's re...
2026-03-06 01:59
Firmable Raises $14m Series A to Take AI-Native Sales Platform Global
MELBOURNE, Australia, March 2, 2026 /PRNewswire/ -- Firmable, Asia-Pacific's leading AI (artificial intelligence) sales platform, has raised$14 million in Series A funding led by Airtree, with participation from existing investors. The funding will support Firmable's expansion tothe United States...
2026-03-03 00:30
6013
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...
2026-02-27 04:34
7437
GTM.io Launches Operating Partner Model to Close the Go-to-Market Execution Gap
Built for scaling B2B technology companies seeking stronger pipeline, more
consistent revenue execution and sustainable customer expansion.
SYDNEY, Feb. 25, 2026 /PRNewswire/ -- GTM.io
2026-02-26 04:00
4215
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...
2026-02-16 22:03
9993
Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...
2026-02-06 20:00
7341
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, to...
2026-01-30 21:00
10265
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....
2026-01-27 21:00
9328
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
AUCKLAND, New Zealand, Jan. 21, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, theMyriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in theJournal of Trauma and Injury. MASTRR is t...
2026-01-23 03:13
5686
Hydrexia to Provide Hydrogen Application Solution to Toyota
SIDNEY, Jan. 22, 2026 /PRNewswire/ -- Hydrexia Pty Ltd, the wholly owned subsidiary of Hydrexia Holding Limited (Hydrexia), a leading hydrogen technology solution provider, announced today that it has secured an order to provide The Toyota Motor Corporation Australia Ltd (TMCA) with a number o...
2026-01-22 23:00
8436
GAC Enters Australia with AION V, M8 PHEV and EMZOOM; Launches Australian Local Strategy to Build a Benchmark Market in the South Pacific
SYDNEY, Jan. 21, 2026 /PRNewswire/ -- On November 18, 2025, GAC hosted its brand and new model launch ceremony inSydney, officially unveiling its Australia Local Strategy—"GAC: Growing Australian Confidence"—the localized implementation of the company's global "One GAC 2.0" strategy. One of the ...
2026-01-22 09:51
4538
Life's Moments App Launches Worldwide on iPhone and Android -- Turning Scattered Photos, Family Memories and Pet Moments into One Organized Family Tree
All Your Family's Memories… Finally Organized ADELAIDE, Australia, Jan. 20, 2026 /PRNewswire/ -- Life's Moments App today announced its global launch on iPhone and Android, giving families and pet owners an intuitive way to capture, store and organize photos, videos, milestones and important rec...
2026-01-20 21:07
6091
SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population * With the SECuRE trial continuing to recruit, a total of n...
2026-01-15 22:02
7547
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...
2026-01-08 22:00
3937
Seeing Machines to unveil 3D Cabin Perception Mapping at CES2026
Pioneering interior sensing technology to advance automotive safety and customer experience CANBERRA, Australia, Jan. 5, 2026 /PRNewswire/ -- Seeing Machines, a global leader in vision-based monitoring technology, today announced it will unveil its next-generation 3D Cabin Perception Mapping sol...
2026-01-05 20:00
4795
Seeing Machines Announces Future Mobility Group, established to deepen integration with Autonomous Vehicle programs
CANBERRA, Australia, Jan. 2, 2026 /PRNewswire/ -- Seeing Machines, a global leader in vision-based monitoring technology, has established a dedicated Future Mobility Group to support increasing demand from the autonomous driving sector and to advance new commercial opportunities as automated vehi...
2026-01-02 21:00
845
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an ...
2025-12-24 22:02
4624
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therap...
2025-12-22 21:00
6756
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5709
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
5699
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
5541
NYSE Content Update: Exchange Turns 234 Ahead of U.S. Semiquincentennial
2026-05-18 21:29
5441
